Objective: To assess epicardial fat volume (EFV), myocardial TG content (MTGC) and metabolic profile in severely obese patients, and to determine whether ectopic fat depots are linked to metabolic disorders or myocardial function. Research design and methods: Sixty-three subjects with normal LV function and no coronary artery disease, including 33 lean (BMI: 21.4 ± 2.0 kg m À2 ) and 30 obese (BMI: 41.8 ± 6 kg m À2 ) patients, underwent 3-T cardiovascular MRI, and anthropometric, biological and visceral abdominal fat (VAT) assessments. EFV was measured by short-axis slice imaging and myocardial (intra-myocellular) TG content was measured by proton magnetic resonance spectroscopy. Results: EFV and MTGC were positively correlated (r ¼ 0.52, Po0.0001), and were both strongly correlated with age, BMI, waist circumference and VAT, but not with severity of obesity. EFV and MTGC were significantly higher in obese patients than in lean controls (141±18 versus 79±7 ml, P ¼ 0.0001; 1.0±0.1 versus 0.6±0.1%, P ¼ 0.01, respectively), but some differences were found between the two cardiac depots: EFV was higher in diabetic obese subjects as compared with that in non-diabetic obese subjects (213±34 versus 141±18 ml, P ¼ 0.03), and was correlated with parameters of glucose tolerance (fasting plasma glucose, insulin and HOMA-IR), whereas MTGC was not. EFV and MTGC were both associated with parameters of lipid profile or inflammation (TGs, CRP). Remarkably, this was VAT-dependent, as only VAT remained independently associated with metabolic parameters (Po0.01). Concerning myocardial function, MTGC was the only parameter independently associated with stroke volume (b ¼ À0.38, P ¼ 0.01), suggesting an impact of cardiac steatosis in cardiac function. Conclusions: These data show that VAT dominates the relationship between EFV, MTGC and metabolic measures, and uncover specific partitioning of cardiac ectopic lipid deposition.
Introduction
Impaired clearance and storage of triglycerides (TGs) in subcutaneous fat lead to ectopic fat deposition in other adipose tissues such as visceral and epicardial fat (EF), and in non-adipose tissues such as liver, skeletal and myocardial muscle. [1] [2] [3] Evidence suggests that cardiac adiposity including EF and myocardial (intra-myocellular) lipid deposition could contribute to the development of cardiovascular disease. [4] [5] [6] [7] Human epicardial adipose tissue is an active fat depot that secretes proatherogenic, proinflammatory and prothrombotic adipo-cytokines. 8, 9 It has been shown that this ectopic fat is associated with the development of atherosclerotic coronary artery disease. [8] [9] [10] [11] [12] [13] [14] [15] [16] Its anatomic location, without any barrier to the adjacent myocardium, enables local paracrine interaction between EF and the myocardium, suggesting that EF could also have a functional and mechanical role in obesity-related dilated cardiomyopathy. 17, 18 Myocardial lipid deposition (that is, lipid accumulation in the myocyte cytoplasm) is also a marker of ectopic fat accumulation. Proposed as an energy source during intensive exercise, it could also reflect an imbalance between energy supply and demand in sedentary insulin-resistant patients. Intra-myocellular lipid accumulation relates to insulin resistance status. 19, 20 Impaired lipid oxidation, oxidative stress and mitochondrial defects are also associated with elevated myocellular lipid content. 17, [19] [20] [21] [22] Previous studies have shown that diabetic obese humans and rodents have elevated hepatic, myocellular and myocardial lipid content, and that treatment with pioglitazone leads to decreased hepatic and myocardial lipid together with improved insulin sensitivity. 23 Assessment of EF volume (EFV) and myocardial TG content (MTGC) has already been validated [24] [25] [26] with the emergence of non-invasive three-dimensional volumetric imaging techniques such as 3-T magnetic resonance imaging (MRI). This technique is also useful to address the relationship between excess myocardial lipids and impaired myocardial function. This is a challenging approach as the heart is always in motion owing to contraction and breathing, and because previous studies have already shown that myocardial TG stores may change rapidly depending on nutritional conditions. [27] [28] [29] [30] MRI was recently used in mildly obese patients to suggest that the increase in MTGC could be associated with cardiac dysfunction. [31] [32] [33] To date, no study has addressed the relationship between EFV and MTGC in morbidly obese patients, a population with an abundance of fat in different depots and a high risk of cardiac failure, 34 because of the relatively small diameter of the MRI magnet bore. In this study, we had the opportunity to quantify EFV and MTGC in a cohort of severely obese subjects using a 70-cm bore, 3-T MRI system. The main objective was to compare EFV and MTGC in lean controls and in patients with morbid obesity, and to determine whether EFV and MTGC are linked to subtle cardiac function abnormalities, before the development of non-ischemic dilated cardiomyopathy related to obesity. The study also investigated the specific partitioning of ectopic lipid deposition in the heart, and whether the two cardiac depots had the same development and similar effects on cardiac function. Finally, the link between these parameters and metabolic risk markers was assessed, and they were compared with the visceral abdominal fat (VAT) amount in order to determine which best reflects metabolic risk.
Materials and methods

Study population
Sixty-three subjects with normal left ventricular (LV) function and no history of heart failure or ischemic coronary heart disease, including 33 lean (body mass index (BMI): 21. 4 ± 2 kg m
À2
) and 30 morbidly obese (13 with type-2 diabetes) (BMI: 41.8 ± 6 kg m À2 ) patients were studied by cardiovascular magnetic resonance using a 70-cm bore, 3-T system. Intentionally, the obese non-diabetic and diabetics had the same BMI.
The lean subjects were all healthy volunteers; none had diabetes or cardiovascular disease, and no subject had been taking medication. Body weight and dietary habits were stable for at least 3 months for all subjects. The obese patients were under stable medical therapy, including antihypertensive and lipid-lowering drugs. Stress test or thallium myocardial scintigraphy with exercise testing or dipyridamole injection allowed us to exclude patients with ischemic coronary disease. No diabetic patient was taking thiazolinediones, agents known to modulate intracellular lipid content. The mean duration of diabetes was 8±2 years and mean HbA1c was 8.7 ± 0.7%.
The protocol was approved by the institutional ethics committee, and all subjects gave their written informed consent before participation.
Anthropometric and biological characterization
All subjects underwent the following procedures: (i) Anthropometric measurements (weight, height, waist, hip and mid-thigh circumference), blood pressure and heart rate assessment, evaluation of adipose distribution (subcutaneous abdominal fat, VAT) by abdominal computed tomography scan at L4-L5. The waist-to-thigh and the thigh circumference-to-BMI ratios were calculated to assess visceral/subcutaneous fat distribution and subcutaneous fat development, respectively; (ii) blood analysis, including lipid profile, glucose profile (fasting plasma glucose (FPG) and insulin (FPI)), HbA1c, biomarkers of inflammation (fibrinogen, high sensitive C-reactive protein (CRP), ferritin, plasminogen activator inhibitor 1 (PAI-1)), and liver enzymes. The insulin-resistance homeostasis model assessment (HOMA) index was calculated as follows (FPG Â FPI)/22.5. 35 Metabolic syndrome was assessed by NCEP-ATPIII.
Cardiovascular MRI Cardiovascular magnetic resonance imaging was performed at 3-T using a Siemens Verio system (Siemens Medical Solutions, Erlangen, Germany).
LV morphology and function
Cardiac structural and functional data were collected using a steady-state, free precession cine sequence optimized to 3 T using four-fold GRAPPA k-space reduction (field of view ¼ 340 Â 340 mm 2 ; echo time (TE) ¼ 1.2 ms; repetition time (TR) ¼ 61 ms; matrix ¼ 134 Â 192; slice thickness ¼ 6 mm). A total of 14-16 continuous short-axis slices were required to cover the left and the right ventricles completely from the apex to the atrioventricular grooves, and were Cardiac adiposity and heart function in obesity B Gaborit et al obtained within short breath holds. End-diastole and endsystole were identified on all short-axis slices. The endocardial and pericardial contours were outlined manually, with inclusion of papillary muscles in the LV cavity to gain better reproducibility. 36 A dedicated post-processing software (Argus; Siemens Medical Solutions) was used to quantify the LV ejection fraction, LV mass, cardiac output, stroke volume (SV), end-diastolic and systolic volume (EDV, ESV). Cardiac, LV mass, SV, EDV and ESV indexes (CI, LV mass i , SV i , EDV i , ESV i ) were calculated by dividing the parameter by the patient's body surface area.
EF volume
EF only included fat between the myocardial border and the internal visceral layer of the pericardium. The border between epicardial and pericardial fat was localized by visual inspection of the entire cine series in all slices ( Figure 1 ). Areas of EF were then traced manually on consecutive endsystolic short-axis images beginning at the mitral valve and ending at the last slice containing cardiac adipose tissue. The areas obtained for each slice were added together and multiplied by slice thickness to yield EFV. EF mass was obtained by multiplying EFV by fat density (0.9196 g ml
À1
).
Proton magnetic resonance spectroscopy: MTGC An ECG-gated, point-resolved, single-voxel proton spectroscopy sequence (PRESS; TE ¼ 32 ms; TR ¼ 810 ms) was used to determine the molecular content of lipids and water. For reference purposes, LV imaging was performed in fourchamber and short-axis views. The spectroscopic volume of interest was positioned using these two perpendicular image series in an end-systolic phase, so as to lie entirely within the intra-ventricular septum. The volume of interest dimensions were 17 Â 15 Â 7 mm 3 . The septum was chosen as a location sufficiently distant from the EF compartments to avoid contamination. In order to acquire fully relaxed magnetization, eight systolic, ECG-gated, single-excitation acquisitions were performed separately in eight breath holds. Spectra were analyzed using an in-house developed software running under an IDL environment (Interactive Data Language; ITT Visual Solutions, Boulder, CO, USA). MTGC was determined by integration in frequency domain and was expressed as a percentage of the water signal (%TG; (TG/water) Â 100).
Statistical analyses
Statistical analysis was performed using SAS version 9.01 (SAS Institute Inc., Cary, NC, USA). Continuous variables are expressed as mean ± s.e. Variables with a skewed distribution were log-transformed. Mean levels were compared by unpaired t-test or analysis of variance. Pearson's test was performed to determine the correlation between markers.
Stepwise multiple linear regression analysis was performed to evaluate independent correlates of ectopic fat depots. The relationship between each metabolic or cardiac function parameter (dependent variable) with a series of explanatory variables (independent variables) was modeled. The parameters successively considered in separate analyses as the outcome variable (dependent variable) were TGs, FPG, FPI, HOMA-IR, fibrinogen, CRP, gamma-glutamyltransferase (GGT), EDV i , ESV i , SV, SV i and CI. P-values o0.05 were considered statistically significant.
Results
Characteristics of the study population
The characteristics of the study population are summarized in Table 1 . Thirty-six percent were men. The mean age was 35 ± 2 years. As the obese patients were significantly older than the lean subjects, all subsequent analyses were adjusted for age. EFV and MTGC were not statistically different between men and women: 138 ± 26 versus 115 ± 9 ml (P ¼ 0.82) and 0.9 ± 0.1% versus 0.9 ± 0.1% (P ¼ 0.96). We Cardiac adiposity and heart function in obesity B Gaborit et al combined men and women for subsequent analysis. Intraand inter-observer reproducibilities of EFV were excellent, with a variation coefficient of 1.9% and 4.5%, respectively. Table 2) . Multivariate analysis including age and clinical anthropometric parameters showed that age, BMI and waist-to-thigh remained independently related to EFV (Po0.0001, P ¼ 0.005, P ¼ 0.03, respectively). Importantly, these three clinical parameters explained 87% of the EFV variance. By contrast, MTGC remained independently associated with age and BMI (both P ¼ 0.02), and these two parameters explained 57% of the MTGC variance.
EFV and MTGC increased with metabolic syndrome (93±8 versus 199 ± 26 ml (Po0.0001) and 0.7 ± 0.4% versus 1.2 ± 0.6% (P ¼ 0.002), respectively) ( Figure 2 ).
As expected, the obese subjects had a significant increase in EFV and MTGC as compared with the lean subjects .0001 between lean, obese and diabetic. The variables are the means ± s.e. All lean subjects had no cardiovascular risk factors. Among the obese patients, 10 were treated for hypertension, 11 for dyslipidemia, six were current smokers and eight had a familial history of coronary artery disease. The subscript i indicates normalization to body surface area.
Cardiac adiposity and heart function in obesity B Gaborit et al (141 ± 18 versus 79 ± 7 ml (P ¼ 0.0001) and 1.0 ± 0.1% versus 0.6 ± 0.1% (P ¼ 0.01), respectively) ( Figure 2) . Surprisingly, no difference was observed in MTGC and EFV between the morbidly obese (BMIX40) and non-morbidly obese (BMIo40 kg m À2 ) subjects, suggesting that severity of obesity is not necessarily associated with an increase in cardiac ectopic fat deposition.
Interestingly, EFV was significantly higher in the obese diabetic subjects as compared with that in the obese nondiabetic subjects (213±34 versus 141±18 ml, P ¼ 0.03), although they had the same BMI (41.9 ± 1 versus 41.9±2 kg m À2 ) ( Figure 2 ). By contrast, MTGC was not statistically different between the obese non-diabetics and the diabetics (P ¼ 0.38). In multivariate analysis, EFV was independently related to the presence of diabetes, even after adjusting for BMI (R 2 ¼ 0.49, P ¼ 0.01).
Correlation between glycemic, lipid and inflammation parameters, and ectopic depots Interestingly, EFV was associated with glucose tolerance: FPG (r ¼ 0.34, P ¼ 0.007), FPI (r ¼ 0.49, P ¼ 0.005) and HOMA-IR (r ¼ 0.44, P ¼ 0.002), whereas MTGC was not, highlighting the difference between the two depots. EFV and MTGC were both associated with lipid and inflammation parameters: EFV and MTGC were both strongly associated with TG (r ¼ 0.53, Po0.0001, and r ¼ 0.29, P ¼ 0.04) and high sensitive CRP (r ¼ 0.37, P ¼ 0.02, and r ¼ 0.44, P ¼ 0.006), but not with high-density lipoprotein or low-density lipoprotein (Table 3) . EFV was also associated with fibrinogen. We examined the same parameters for VAT and observed that VAT was correlated with exactly the same parameters as EFV, and in addition with PAI-1 (r ¼ 0.63, P ¼ 0.004).
To test the independent relationship between each cardiac depot, metabolic risk and VAT, these correlations were re-determined after adjustment for VAT. Cardiac adiposity and LV function All patients had a normal LV ejection fraction ( Table 1 ). The obese and diabetic patients had higher LV mass, decreased normalized end-diastolic and end-systolic volume (EDV i , ESV i ), normalized stroke volume (SV i ) and CI as compared with the lean subjects. MTGC was the only cardiac depot negatively associated with SV (r ¼ À0.28, P ¼ 0.04) ( Table 4) , and this correlation remained statistically significant after adjusting for BMI or body surface area (R 2 ¼ 0.11, P ¼ 0.01; Tables 5   and 6 ). Both cardiac depots were correlated with parameters of LV volume and function indexed to body surfaces; the correlations between MTGC and cardiac function parameters remained statistically significant after adjusting for BMI (Supplementary Table 5 ).
Discussion
To our knowledge, this is the first study to investigate EFV and MTGC in a large group of subjects, including morbidly obese patients. These two fat depots do not accumulate similarly and are associated with different phenotypes. While EFV was highly correlated with visceral fat and metabolic risk factors, MTGC was independently associated with subtle cardiac abnormalities. Most studies have focused on pericardial lipid accumulation. 12, 14, 31, [37] [38] [39] However, only EF surrounds the adventitia of coronary arteries without any fibrous layer, and its embryological origin is different from that of pericardial fat. 7 Although it is difficult to differentiate these two fat depots in lean subjects, it was considered important to make this distinction in our study. The precision and reproducibility of MRI enables this distinction. 25 EFV is an important fat depot and its abundance was clearly associated with the presence and severity of coronaropathy. 8, 15, 40 An inflammatory profile in patients with coronary disease was also enlightened, suggesting a pathophysiological link between EFV and the development or aggravation of coronaropathy. 5, 8, 9, 41 This study provides a detailed characterization of the metabolic, inflammatory and cardiovascular parameters associated with EFV. In agreement with previous autopsy studies, or studies using Cardiac adiposity and heart function in obesity B Gaborit et al echography or computed tomography, EFV increases with age, BMI and waist circumference. 15, 16, 37, 42 Surprisingly, EFV was not correlated with LV mass or EDV. Previous studies showed similar results. 31, 43 According to the ectopic fat theory, 1,2 when subcutaneous adipose tissue appears unable to store energy excess (because it is lacking or is dysfunctional), a surplus of triacylglycerol accumulates at undesirable sites such as the liver, heart, skeletal muscle, and possibly in visceral adipose tissue. 20, 22, 44, 45 In agreement with this hypothesis, EFV was directly related to the absence of accumulation of subcutaneous fat in obese patients, and was related to waist-to-thigh circumference and thigh circumference-to-BMI. Furthermore, EFV did not increase with the severity of obesity and was strongly correlated with VAT. This study confirms that EFV increases with diabetes, suggesting that EF contributes to the association between diabetes and cardiovascular risk. EFV was also found to be a good predictor of metabolic risk and was highly associated with glycemic parameters (FPG, FPI, HOMA), lipid (TG) and inflammation parameters (CRP, fibrinogen). The relative importance of VAT or EFV in the prediction of metabolic syndrome is a matter of debate. 16, 31 Computed tomography measurement of EF thickness in the left atrioventricular groove was proposed as a more accurate assessment of metabolic risk than VAT. 16 A recent study by Iozzo et al. 31 in 53 subjects, separated according to glucose tolerance, reported that pericardial fat and myocardial fat were independently related to plasma glucose levels, but the authors did not account for VAT. Here, it is clearly shown that the link between EFV, MTGC and markers of metabolic risk was dependent on the amount of VAT, as these correlations did not remain significant after adjustment for VAT. These results are consistent with the Framingham Heart Study, 37 showing that only VAT remained associated with FPG in a large population after multiple adjustments. Based on these findings, it is hypothesized that EF is a potent marker of visceral fat depots, but that VAT remains the determinant marker of obesity-related metabolic risk. One physiopathological explanation is its unique anatomic location, which allows the release of free fatty acids and adipokines into the portal vein for direct transport to the liver and pancreas, thus directly influencing metabolism. Importantly, MTGC was associated with EFV. EF was shown to be a particularly inflammatory adipose tissue with important lipolytic activity. It has been shown in cellular models that fatty acid release from adipocytes is strongly stimulated by inflammation. 46 Animal studies have shown that the rate of fatty acid breakdown and insulin-induced lipogenesis was significantly higher in EF as compared with that in other fat depots. 47 The anatomic location of EF, without Cardiac adiposity and heart function in obesity B Gaborit et al any barrier to the adjacent myocardium, allows local paracrine interactions between EF and the myocardium. 48 EF could directly supply myocardial cells with fatty acids. Furthermore, it is suggested that inflammatory signals produced by EF, associated with low levels of adiponectin, may increase the membrane localization of CD36 in cardiomyocytes and consequently increase myocardial lipid uptake. Cardiac adiposity and heart function in obesity B Gaborit et al EFV and MTGC are related to each other, but do not accumulate in a similar way. The molecular characteristics of EF are perhaps as important as EFV. Indeed, important molecular differences have been shown between EF in patients with or without coronaropathy. Furthermore, short therapeutic interventions may drastically modulate the lipolytic and inflammatory characteristics of adipose tissue. 41 Surprisingly, MTGC was not related to subcutaneous adipose tissue indices (that is, thigh circumference-to-BMI ratio). This result was also observed by Iozzo et al., 31 who found no correlation between abdominal subcutaneous adipose tissue and MTGC, whereas this association was present with pericardial fat mass. Understanding the early mechanisms of obesity-related cardiomyopathy is vital as the prevalence, morbidity and cost of this disease continue to increase. We chose to exclude patients with coronary artery disease and heart failure in order to analyze the early abnormalities of cardiac function linked to obesity and observed that MTGC was negatively correlated with stroke volume. Previous studies have suggested an association between pericardial fat and cardiac function. 31, 32 Kankaanpaa et al. 32 showed in a very limited population (n ¼ 9) that EF was inversely correlated with CI. By contrast, Iozzo et al. showed that MTGC was independently and positively associated with cardiac output, LV forward work, cardiac work and CI, but not with pericardial fat. Nevertheless, their patients had coronary artery disease, which may have influenced the results. 31 Our results suggest that early myocardial TG accumulation may lead to lipotoxic injury to the myocardium. Indeed, animal studies support a causal link between myocardial dysfunction and cellular lipid accumulation. 6, 20, 22 Our study has several limitations. EFV was strongly correlated with age and obese patients were older than lean subjects. Age could have been a confounder as EFV was higher in obese and diabetic patients. Nevertheless, all our results remained significant after age adjustment.
49
Our results reinforce the importance of cardiac steatosis and highlight the connection and differences between the two cardiac fat depots. These results, in association with recent results in the literature, suggest that VAT is the best marker of metabolic risk, EFV the best predictor of coronary artery disease and MTGC could be a predictor of early myocardial dysfunction. Prospective studies might better address the question of ectopic fat depots and cardiac dysfunction.
